BOSTON, Massachusetts, March 26, 2026
PureTech Health has announced that its founded entity, Seaport Therapeutics, has published first-in-human clinical and preclinical data for GlyphAllo™ (SPT-300) in Science Translational Medicine. The findings demonstrate that GlyphAllo is the first triglyceride-mimetic prodrug to achieve therapeutically relevant drug levels in humans, representing a significant breakthrough in oral drug delivery and neuropsychiatric treatment development, particularly for major depressive disorder (MDD).
First-in-Human Data Validates Novel Drug Delivery Platform
The published research provides comprehensive evidence supporting the clinical validation of Seaport’s proprietary Glyph™ platform, a novel technology designed to enable oral delivery of therapeutics by bypassing liver metabolism through lymphatic transport. GlyphAllo, an oral prodrug of allopregnanolone, was developed to overcome the bioavailability limitations associated with traditional formulations, which often suffer from rapid metabolism and reduced systemic exposure.
Clinical data from Phase 1 and Phase 2a studies demonstrated that GlyphAllo achieved dose-dependent, therapeutically relevant plasma concentrations, confirming its ability to deliver effective drug exposure in humans. The therapy was also found to be generally well tolerated across a range of doses, supporting its safety profile and suitability for further clinical development. These results represent a critical milestone in advancing oral neuropsychiatric therapies, which have historically faced challenges related to pharmacokinetics and drug delivery.
Promising Efficacy Signals in Depression and Stress Response
Advertisement
In addition to pharmacokinetic validation, the studies demonstrated strong pharmacodynamic effects, including significant reductions in stress-related biomarkers. In a Phase 2a proof-of-concept trial using the Trier Social Stress Test (TSST), a single dose of GlyphAllo resulted in a statistically significant reduction in salivary cortisol levels compared to placebo (p=0.0001), indicating its ability to modulate acute stress responses.
These findings support the potential of GlyphAllo as a rapid-acting and durable therapeutic option for major depressive disorder, a condition with substantial unmet medical need. The therapy is designed to leverage the clinically validated effects of allopregnanolone, including antidepressant, anxiolytic, and sleep-promoting properties, while improving its oral bioavailability and patient convenience.
The results have supported the advancement of GlyphAllo into an ongoing global Phase 2b clinical trial (BUOY-1), which is evaluating its efficacy, safety, and tolerability in adults with MDD, including patients with or without anxious distress.
Broad Platform Potential Across Multiple Therapeutic Areas
Beyond GlyphAllo, the Glyph™ platform represents a versatile and scalable drug delivery technology with potential applications across a wide range of therapeutic areas. By enabling drugs to be absorbed through the intestinal lymphatic system, the platform can bypass first-pass metabolism, improving bioavailability and reducing adverse effects such as hepatotoxicity.
This approach has significant implications for the development of therapies in oncology, immunology, metabolic diseases, and inflammation, where drug delivery challenges often limit clinical success. The ability to transform existing molecules into optimized oral prodrugs with improved pharmacokinetic profiles positions the Glyph platform as a valuable innovation in pharmaceutical development.
The publication in a high-impact, peer-reviewed journal further reinforces the scientific credibility and translational potential of the platform, highlighting its role in advancing next-generation precision therapeutics.
The publication of GlyphAllo data in Science Translational Medicine marks a significant milestone in the evolution of oral drug delivery and neuropsychiatric treatment development. With strong clinical validation, promising efficacy signals, and a novel mechanism of delivery, GlyphAllo represents a potential breakthrough therapy for major depressive disorder.
As development progresses, the Glyph platform is expected to play a transformational role in overcoming key limitations in drug bioavailability, enabling more effective and patient-friendly therapies across multiple disease areas. This advancement underscores the growing importance of innovative delivery technologies in modern biopharmaceutical research, positioning PureTech and Seaport at the forefront of next-generation therapeutic innovation.
Source: PureTech Health, Seaport Therapeutics press release
